ArticleDrug design, development and therapy2025
Optimal Propofol Dose with Oxycodone for Visceral Pain Relief in Anxious Patients Undergoing Abortion: A Clinical Trial Report.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of Incidence of Respiratory Depression Between Ciprofol versus Propofol for Procedural Sedation During First-Trimester Surgical Abortion: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Dixon Up-and-Down Method for Optimizing Oxycodone Dosage in Painless Colonoscopy.Journal of pain research · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction/Objective: Patients undergoing induced abortion frequently experience acute visceral pain and preoperative anxiety, the latter of which is known to increase anesthetic requirements. This study aimed to determine the median effective dose (ED50) and the 95% effective dose (ED95) of propofol in combination with oxycodone for alleviating visceral pain, specifically testing the finding that anxiety increases the needed propofol dose. Methods: Female patients, who were scheduled for elective abortion surgeries, with PAS-7 ≥8 were classified as anxious group (Group A), while those with PAS-7 < 8 were classified as non-anxious group (Group N). Both groups received an intravenous dose of 0.10 mg/kg of oxycodone prior to surgery.And 2 to 3 minutes later, the first patient in the sequence received an initial dose of 3.50 mg/kg of propofol, with subsequent doses determined by Dixon's up-and-down method. Results: The ED50 (95% CI) for propofol was 1.96 mg/kg (1.87-2.05) in Group N and 2.42 mg/kg (2.30-2.53) in Group A; the ED95 (95% CI) was 2.10 mg/kg (2.03-2.39) and 2.60 mg/kg (2.50-2.95), respectively. The lack of overlap in the 95% confidence intervals indicates a statistically significant difference between groups. Conclusion: The combination of 0.10 mg/kg oxycodone and propofol was effective for visceral pain suppression during artificial abortion. Notably, patients with anxiety required higher doses of propofol to achieve satisfactory pain relief during abortion surgeries. Trial Registration: This human study was approved by the Medical Ethics Committee of the People's Hospital of Qiannan (QNZY-QNYZKYRC-23-0801) and registered at https://www.chictr.org.cn/ (Date: 09/26/2023, ChiCTR2300076169).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.